Dendreon Corporation
http://www.dendreon.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dendreon Corporation
COVID-19 DNA Vaccine Halt Another Blow To AnGes
AnGes has terminated R&D work on a DNA vaccine for COVID-19 and will now look at intranasal candidates with a US partner. Although the original project received funding from the Japanese government, a spike in related costs caused the Japanese firm's net loss to triple last year, and the decision represents the latest in a string of pipeline setbacks.
Japan’s Biopharma Excellence Celebrated At Pharma Intelligence Awards
Excellence, innovation, deal-making and individual achievement across the Japanese biopharma sector were celebrated at the inaugural Pharma Intelligence Japan Awards 2022 in Tokyo on 1 September.
Japan’s Biopharma Excellence Celebrated At Pharma Intelligence Awards
Excellence, innovation, deal-making and individual achievement across the Japanese biopharma sector were celebrated at the inaugural Pharma Intelligence Japan Awards 2022 in Tokyo on 1 September.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Corvas
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice